Comparação indirecta da eficácia, segurança e tolerabilidade do Dolutegravir em regime duplo e Dolutegravir em regime triplo no tratamento de pacientes com HIV- 1

Abstract

The Human Immunodeficiency Virus type 1 (HIV-1) is responsible for Acquired Immunodeficiency Syndrome (AIDS), a condition that results in the progressive deterioration of the immune system, compromising the body's ability to fight infections. In this sense, there are several scientific studies in search of a cure for AIDS and recent results suggest that Dolutegravir (DTG) and Lamivudine (3TC) may be an effective, safe and better tolerated treatment regimen. This study used an indirect method (Bucher method) to compare scientific evidence on the efficacy, safety and tolerability of the DTG/3TC regimen in relation to the triple regimens (DTG/3TC + ABC/TDF) in the treatment of patients with HIV-1. The research was conducted in accordance with PRISMA guidelines, covering both gray literature and renowned databases, such as PubMed and Science Direct. A total of six (6) studies were included, whose results, based on the Bucher method, suggest that the DTG/3TC regimen presents non-inferior efficacy compared to triple treatment regimens (DTG/3TC+ABC/TDF). In addition, the DTG/3TC regimen demonstrated advantages in terms of safety and tolerability, presenting a lower incidence of adverse events, with statistically significant differences (p=0.0 and p=0.006) at weeks 48 and 144, respectively. The absence of TDF in the DTG/3TC regimen helps to reduce the risk of treatment-associated nephrotoxicity. These long-term data reinforce the therapeutic value of DTG/3TC for patients living with HIV-1. (TRADUÇAO NOSSA)